The Role of Metoprolol and Enalapril in the Prevention of Doxorubicin-induced Cardiotoxicity in Lymphoma Patients
| Autor: | Apostolos Karavidas, Andriani Charpidou, Anastasia Perpinia, Marousa Kouvela, Peter Georgakopoulos, Stelios Zimeras, Michael Kyriakidis, Nikolaos Mamalis |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Heart disease Adolescent Lymphoma medicine.medical_treatment 03 medical and health sciences 0302 clinical medicine Enalapril Internal medicine medicine Humans Doxorubicin Anthracyclines Prospective Studies Metoprolol Heart Failure Chemotherapy Cardiotoxicity Antibiotics Antineoplastic business.industry General Medicine medicine.disease Oncology Echocardiography 030220 oncology & carcinogenesis Concomitant Heart failure Cardiology Female business medicine.drug |
| Zdroj: | Anticancer research. 39(10) |
| ISSN: | 1791-7530 |
| Popis: | Background/aim Anthracyclines, such as doxorubicin, though widely used in anticancer therapy, they are associated with cardiotoxic side-effects. The aim of this trial was to investigate long-term follow-up cardiotoxicity findings in patients treated with doxorubicin and concomitant metoprolol or enalapril 10 years earlier. Patients and methods Overall, 147 patients were randomized into the treatment arms. A total of 125 patients treated with doxorubicin without evidence of heart disease at the start of chemotherapy were analyzed. They were followed-up for up to 10 years after treatment start. Results and conclusion A total of 47 patients completed the follow-up and 21 patients died, none due to cardiotoxicity events. Clinical signs of heart failure were not seen in any patients and no statistically significant differences between baseline and 10-year findings were seen for echocardiographic variables. No evidence of long-term cardiotoxicity was seen and nor metoprolol or enalapril offered an additional benefit. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|